We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary
- Authors
Cluck, David B.; Chastain, Daniel B.; Murray, Milena; Durham, Spencer H.; Chahine, Elias B.; Derrick, Caroline; Dumond, Julie B.; Hester, E. Kelly; Jeter, Sarah B.; Johnson, Melissa D.; Kilcrease, Christin; Kufel, Wesley D.; Kwong, Jeffrey; Ladak, Amber F.; Patel, Nimish; Pérez, Sarah E.; Poe, Jonell B.; Bolch, Charlotte; Thomas, Ian; Asiago‐Reddy, Elizabeth
- Abstract
Treatment options are currently limited for persons with HIV‐1 (PWH) who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1. In addition, future areas of research are also identified and discussed in the main document.
- Subjects
AMERICAN College of Clinical Pharmacy; UNITED States. Food &; Drug Administration; HIV; PHARMACY colleges; DELPHI method; ANTI-HIV agents; ANTIRETROVIRAL agents
- Publication
Pharmacotherapy, 2024, Vol 44, Issue 5, p354
- ISSN
0277-0008
- Publication type
Article
- DOI
10.1002/phar.2913